Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
US Army
McKesson
Teva
Chinese Patent Office
Federal Trade Commission
Cerilliant
Farmers Insurance
Express Scripts

Generated: April 24, 2018

DrugPatentWatch Database Preview

CORTEF Drug Profile

« Back to Dashboard

When do Cortef patents expire, and when can generic versions of Cortef launch?

Cortef is a drug marketed by Pharmacia And Upjohn and is included in five NDAs.

The generic ingredient in CORTEF is hydrocortisone acetate. There are sixty-four drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the hydrocortisone acetate profile page.
Drug patent expirations by year for CORTEF
Pharmacology for CORTEF
Synonyms for CORTEF
[2-[(8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] 3-cyclopentylpropanoate
11,17-Dihydroxy-3,20-dioxopregn-4-en-21-yl 3-cyclopentylpropanoate, (17.alpha.,21.beta.)
11beta,17,21-Trihydroxypregn-4-ene-3,20-dione 21-cyclopentanepropionate
17-(3-cyclopentyl-1-propionyl)-11beta,17alpha,21-trihydroxypregn-4-ene-3,20-dione
17-Hydroxycorticosterone 21.beta.-cyclopentylpropionate
17-Hydroxycorticosterone 21beta-cyclopentylpropionate
2-((8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl 3-cyclopentylpropanoate
2-[(1S,2R,10S,11S,14R,15S,17S)-14,17-DIHYDROXY-2,15-DIMETHYL-5-OXOTETRACYCLO[8.7.0.0(2),?.0(1)(1),(1)?]HEPTADEC-6-EN-14-YL]-2-OXOETHYL 3-CYCLOPENTYLPROPANOATE
4XDY25L70B
508-99-6
AC1L5CF4
AK398666
AKOS027382851
BDBM50371265
C08176
C29H42O6
CHEBI:5783
CHEMBL1549
Cortef fluid
Cortef oral suspension
Cortisol 21-cyclopentanepropionate
cortisol cypionate
Cortisol, 21-cyclopentanepropionate
Cortisol, 21-cyclopentanepropionate (8CI)
CS-7123
D00976
DLVOSEUFIRPIRM-KAQKJVHQSA-N
DTXSID90872930
EINECS 208-091-0
HY-U00089
Hydrocortisone 21.beta.-cyclopentanepropionate
Hydrocortisone 21beta-cyclopentanepropionate
Hydrocortisone cipionate
Hydrocortisone cyclopentyl propionate
Hydrocortisone Cyclopentylpropionate
HYDROCORTISONE CYPIONATE
Hydrocortisone cypionate [USP]
Hydrocortisone cypionate(200 mg)
HYDROCORTISONECYPIONATE
LMST02030121
MLS002638159
NCI60_000174
NSC 10721
NSC-10721
NSC10721
PL009716
Pregn-4-ene-3, 21-(3-cyclopentyl-1-oxopropoxy)-11,17-dihydroxy-, (11.beta.)-
Pregn-4-ene-3,20-dione, 21-(3-cyclopentyl-1-oxopropoxy)-11,17-dihydroxy-, (11.beta.)-
Pregn-4-ene-3,20-dione, 21-(3-cyclopentyl-1-oxopropoxy)-11,17-dihydroxy-, (11beta)-
SCHEMBL41673
UNII-4XDY25L70B
ZINC4097470

US Patents and Regulatory Information for CORTEF

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pharmacia And Upjohn CORTEF hydrocortisone INJECTABLE;INJECTION 009864-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Pharmacia And Upjohn CORTEF ACETATE hydrocortisone acetate OINTMENT;TOPICAL 008917-002 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Pharmacia And Upjohn CORTEF hydrocortisone TABLET;ORAL 008697-001 Approved Prior to Jan 1, 1982 AB RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Pharmacia And Upjohn CORTEF ACETATE hydrocortisone acetate OINTMENT;TOPICAL 008917-001 Approved Prior to Jan 1, 1982 DISCN Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Colorcon
US Department of Justice
UBS
Harvard Business School
Federal Trade Commission
Dow
Daiichi Sankyo
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.